Novartis/Idenix Report Mixed Interim Data For Hep C Candidate Valopicitabine
This article was originally published in The Pink Sheet Daily
Idenix will await full 72-week data and data from another combination study before deciding the fate of the HCV therapy.
You may also be interested in...
Proof of concept study evaluating polymerase/protease inhibitor combinations for HCV could start within the next year, Vertex predicts.
Novartis has exercised its option to license valopicitabine from Idenix in spite of gastrointestinal side effects seen in clinical trials.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.